Work

Enfortumab Vedotin (EV) in the Previously Treated Advanced Head and Neck Cancer (HNC) Cohort of EV-202

Year: 2024

Type: article

Study design: Clinical Trial

Source: International Journal of Radiation Oncology*Biology*Physics

DOI: 10.1016/j.ijrobp.2024.01.043

Authors: P.L. Swiecicki, E. Yilmaz, A.J. Rosenberg, T. Fujisawa, J.Y. Bruce, C. Meng, M.A. Wozniak, L. Wang, S. Gorla, J.L. Geiger

Institutions: University of Michigan, Cleveland Clinic, University of Chicago, National Cancer Center Hospital East, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Seagen (United States), Astellas Pharma (United States)

Language: English

Topic: Head and Neck Cancer Studies

Subfield: Otorhinolaryngology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4392797391

FWCI: 0.782

Cites:

Cited by: 2

Related to: 10